Evidence map›Paper›PMID 34697143›Full record

ArticleIn vivo (Athens, Greece)

Suppression of Tumor Growth in a Rabbit Hepatic Cancer Model by Boron Neutron Capture Therapy With Liposomal Boron Delivery Systems.

Hironobu Yanagie, Masashi Yanagawa, Yasuyuki Morishita, Atsuko Shinohara, Novriana Dewi, Yasumasa Nonaka, Yoshitaka Furuya, Ryouji Mizumachi, Yuuji Murata, Hiroyuki Nakamura and 11 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 1 country.

Hironobu YanagieInstitute of Engineering Innovation, School of Engineering, The University of Tokyo, Tokyo, Japan; h.yanagie@gmail.com.
Masashi YanagawaVeterinary Medical Center, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Japan.
Yasuyuki MorishitaDepartment of Human and Molecular Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Atsuko ShinoharaGraduate School of Humanities, Seisen University, Tokyo, Japan.
Novriana DewiLaboratory of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
Yasumasa NonakaDepartment of Surgery, Keiai-kai Houyou Hospital, Hanamaki, Japan.
Yoshitaka FuruyaDepartment of Surgery, Sodegaura Satukidai Hospital, Sodegaura, Japan.
Ryouji MizumachiDepartment of Pharmacology, Kumamoto Institute Branch, LSI Medience Ltd. Co., Uto, Japan.
Yuuji MurataDepartment of Pharmacology, Kumamoto Institute Branch, LSI Medience Ltd. Co., Uto, Japan.
Hiroyuki NakamuraLaboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, Japan.
Minoru SuzukiInstitute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan.
Yoshinori SakuraiInstitute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan.
Hiroki TanakaInstitute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan.
Shinichiro MasunagaInstitute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan.
Koji OnoBNCT Joint Clinical Institute, Osaka Medical Pharmaceutical University, Osaka, Japan.
Takumichi SugiharaLaboratory of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
Masayuki NashimotoResearch Institute of Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
Haruo YamauchiCooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan.
Minoru OnoCooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan.
Jun NakajimaCooperative Unit of Medicine and Engineering, The University of Tokyo Hospital, Tokyo, Japan.
Hiroyuki TakahashiInstitute of Engineering Innovation, School of Engineering, The University of Tokyo, Tokyo, Japan.
Kyoto University · JPNiigata University of Pharmacy and Applied Life Sciences · JPUniversity of Tokyo Hospital · JPObihiro University of Agriculture and Veterinary Medicine · JPOsaka University of Pharmaceutical Sciences · JPSeisen University · JPThe University of Tokyo · JPTokyo Institute of Technology · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimTumor cell destruction by boron neutron capture therapy (BNCT) is attributed to the nuclear reaction between MATERIALS AND

methodsWe prepared

resultsConcentrations of

conclusionThe present results demonstrate the applicability of

Indexed as

Boron Neutron Capture TherapyLiver NeoplasmsAnimalsBoronLiposomesRabbitsBoronLiposomes10B-borono-dodecaborate 10BSHBNCTBoron neutron capture therapydistearoylboron lipidDSBLHCChepatocellular carcinomaliposomePEGtransferrin-conjugated polyethylene glycol

Identifiers

PMID34697143
PMCPMC8627757
OpenAlexW3209382101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.